Stacy Dixon, MD, PhD
Assistant Professor, Neurology

Teaching

Publications

• Phillips J, Dixon S, Koehler T, Kluger B. Advance Care Planning Among Patients With Amyotrophic Lateral Sclerosis: Patient Perspectives on Goals of Care Conversations. Am J Hosp Palliat Care. 2023 Apr 27;:10499091231172901. [Epub ahead of print] PubMed PMID: 37128837
• Meisel A, Annane D, Vu T, Mantegazza R, Katsuno M, Aguzzi R, Frick G, Gault L, Howard JF Jr. Long-term efficacy and safety of ravulizumab in adults with anti-acetylcholine receptor antibody-positive generalized myasthenia gravis: results from the phase 3 CHAMPION MG open-label extension. J Neurol. 2023 Aug;270(8):3862-3875. PubMed PMID: 37103755
• Lafreniere M, Dixon SE, Kammeyer R, Declusin A, “Cognitive changes, weakness, and myoclonus in a 78-year old man: a case presentation.” Carrell-Krusen Neuromuscular Symposium, Dallas, TX (February 2023, poster presentation).
• Dixon S, Kang X, Quan, D. Practical Guidance for the Use of Patisiran in the Management of Polyneuropathy in Hereditary Transthyretin-Mediated Amyloidosis. Therapeutics and Clinical Risk Management 2023:19 973–981.
• Vu T, Meisel A, Mantegazza R, Annane D, Katsuno M, Aguzzi R, Enayetallah A, Beasley KN, Rampal N, Howard JF, CHAMPION MG Study Group. Terminal Complement Inhibitor Ravulizumab in Generalized Myasthenia Gravis. NEJM Evid. 2022; 1 (5)
• Lafreniere M, Dixon SE, “Thoughts and Perceptions of Risdiplam from Adults with SMA.” CureSMA Researcher and Clinical Care Meeting, Anaheim, CA (June 2022, Poster presentation).
• Petluru M, Dixon SE, “Worsening Upper Extremity Weakness Seen as a Side Effect of Risdiplam in Adults with Spinal Muscular Atrophy.” CureSMA Researcher and Clinical Care Meeting, Anaheim, CA (June 2022, Poster presentation).
• Chen E, Dixon S, Naik R, Noone JM, Buchenberger JD, Whitmire SM, Mills R, Arnold W. Early experiences of nusinersen for the treatment of spinal muscular atrophy: Results from a large survey of patients and caregivers. Muscle Nerve. 2021 Mar;63(3):311-319. PubMed PMID: 33184859
• Monnette A, Chen E, Hong D, Bazzano A, Dixon S, Arnold WD, Shi L. Treatment preference among patients with spinal muscular atrophy (SMA): a discrete choice experiment. Orphanet J Rare Dis. 2021 Jan 20;16(1):36. PubMed PMID: 33472673
• Chen E., Dixon, S.E., Naik, R., Noone, J., Buchenberger, D., Whitmire, S., Mills, R., Arnold, W. (2021). Early experiences in the treatment of spinal muscular atrophy: Results from a large survey of patients and caregivers. Muscle & Nerve, 63(13), 311-319.
• Monnette, A., Chen, E., Hong, D., Bazzano, A., Dixon, S.E., Arnold, WD., Shi, L. (2021). Treatment preference among patients with spinal muscular atrophy (SMA): a discrete choice experiment. Orphanet Journal of Rare Diseases, 20;16(1):36
• Adams D, Polydefkis M, González-Duarte A, Wixner J, Kristen AV, Schmidt HH, Berk JL, Losada López IA, Dispenzieri A, Quan D, Conceição IM, Slama MS, Gillmore JD, Kyriakides T, Ajroud-Driss S, Waddington-Cruz M, Mezei MM, Planté-Bordeneuve V, Attarian S, Mauricio E, Brannagan TH 3rd, Ueda M, Aldinc E, Wang JJ, White MT, Vest J, Berber E, Sweetser MT, Coelho T; patisiran Global OLE study group. Long-term safety and efficacy of patisiran for hereditary transthyretin-mediated amyloidosis with polyneuropathy: 12-month results of an open-label extension study. Lancet Neurol. 2021 Jan;20(1):49-59.
• Arnold, WD., Chen, E., Naik, R., Noone, J., Whitmire, S., Buchenberger, D., Dixon, S.E. Clinical Experience of Spinal Muscular Atrophy (SMA) Treatment: Physician’s Perspective.
• Chen E., Naik, R., Noone, J., Buchenberger, D., Whitmire, Dixon, S.E, S., Arnold, WD. Early experiences in the Treatment of Spinal Muscular Atrophy: Results from a large survey of patients and caregivers.
• Chen, E., Bawa, K., Noone, J., Whitmire, S., Buchenberger, D., Arnold, WD., Dixon, S.E. Impact of Spinal Muscular Atrophy on Caregivers’ Daily Activities and Health-related Quality of Life.
• Monnette, A., Chen, E., Hong, D., Bazzano, A., Dixon, S., Arnold, WD., Shi, L., Treatment Preference among Patients with Spinal Muscular Atrophy (SMA): A Discrete Choice Experiment.